Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study

CONTEXT: Cyproterone acetate (CPA) is a competitive inhibitor of the androgen receptor and exerts negative hypothalamic feedback. It is often used in combination with estrogens in trans women to achieve feminization. However, CPA has been associated with side effects such as changes in liver enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuijpers, Suzanne M E, Wiepjes, Chantal M, Conemans, Elfi B, Fisher, Alessandra D, T’Sjoen, Guy, den Heijer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Online Only Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571811/
https://www.ncbi.nlm.nih.gov/pubmed/34125226
http://dx.doi.org/10.1210/clinem/dgab427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571811/
https://www.ncbi.nlm.nih.gov/pubmed/34125226
http://dx.doi.org/10.1210/clinem/dgab427

Ejemplares similares